Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy-Reference-Cited by-同舟云学术

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

Published:2022-11-11 Issue:12 Volume:6 Page:e798
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Argnani Lisa,Broccoli Alessandro,Pellegrini Cinzia,Fabbri Alberto,Puccini Benedetta,Bruna Riccardo,Tisi Maria Chiara,Masia Francesco,Flenghi Leonardo,Nizzoli Maria Elena,Musso Maurizio,Salerno Marilena,Scalzulli Potito Rosario,Dessi’ Daniela,Ferrarini Isacco,Pennese Elsa,Lucchini Elisa,Rossi Francesca Gaia,Minoia Carla,Gherlinzoni Filippo,Musto Pellegrino,Patti Caterina,Stefoni Vittorio,Zinzani Pier Luigi

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference18 articles.

1. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.;Moore;J Oncol Pharm Pract,2022

2. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.;Palanca-Wessels;Lancet Oncol,2015

3. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).;Morschhauser;Lancet Haematol,2019

4. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.;Sehn;J Clin Oncol,2020

5. Polatuzumab vedotin for the treatment of relapsed/refractory diffuse large B-cell lymphoma in transplant-ineligible patients.;Douglas;J Adv Pract Oncol,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes of the efficacy and safety of polatuzumab vedotin combination regimen in patients with relapsed/refractory diffuse large B cell lymphoma;2024-01-22

2. Second Line Treatment of DLBCL: Evolution of Options;Seminars in Hematology;2023-12

3. Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies;Cells;2023-07-14

4. Bendamustine/polatuzumab vedotin/rituximab;Reactions Weekly;2023-02-04